Read the News and Earn Credit - Click for Credit

For news and views that matter to pediatricians
Click here »

Pediatric Acne Management: Optimizing Outcomes


Bookmark and Share
11/01/11

A CME-Certified Supplement to Skin & Allergy News, supported by an educational grant from Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc. This journal supplement is jointly sponsored by University of Louisville Continuing health Sciences Education and Skin Disease Education Foundation.

  • Table of Contents
  • Faculty/Faculty Disclosure Statement
  • Statement of Professional Practice Gap(s)
  • Target Audience
  • Learning Objectives
  • Joint Sponsorship Statement
  • Designation Statement


To view the supplement, click the image above.

 


To view the supplement, click the image above

 


To view the supplement, click the image above.

Table of Contents

  • Introduction
  • Acne Life Cyle: The Spectrum of Pediatric Disease
  • The Acne Continuum: An Age-Based Approach to Therapy
  • The Effects of Culture, Skin Color, and Other Nonclinical Issues on Acne Treatment
  • Approach to Pediatric Acne Treatment: An Update
  • Parents as Partners in Pediatric Acne Management
  • CME Post-Test and Evaluation

 

Faculty/Faculty Disclosure Statement

Lawrence F. Eichenfield, MD (chair)

Clinical Professor of Pediatrics and Medicine (Dermatology)

Chief, Pediatric and Adolescent Dermatology

Rady Children’s Hospital

University of California San Diego

San Diego, California

 

Lawrence F. Eichenfield, MD, has served as an investigator for Galderma, GlaxoSmithKlein, Johnson & Johnson, Neutrogena, and Stiefel. He has also been a consultant and/or served on the advisory board for Coria, Galderma, GlaxoSmithKlein, Intendis, Medicis, Ortho Dermatologics, Stiefel, and Valeant.

 

Hillary E. Baldwin, MD

Associate Professor

Department of Dermatology

SUNY Downstate

Brooklyn, New York

 

Hilary E. Baldwin, MD, has served as a consultant and speaker for Allergan, Galderma, Medicis, and Onset. She has also been a speaker for GlaxoSmithKlein and Ortho Dermatologics.

 

Sheila Fallon Friedlander, MD

Clinical Professor of Pediatrics and Medicine (Dermatology)

Rady Children’s Hospital

University of California San Diego

San Diego, California

 

Sheila Fallon Friedlander, MD, has served on an advisory board for Galderma and Onset.

 

Anthony J. Mancini, MD

Professor of Pediatrics and Dermatology

Northwestern University Feinberg School of Medicine

Head, Division of Pediatric Dermatology

Children’s Memorial Hospital

Chicago, Illinois

 

Anthony J. Mancini, MD, has served as a consultant for Galderma, Medicis, and Stiefel. He has also been a speaker for Galderma.

 

Albert C. Yan, MD

Chief, Pediatric Dermatology

Children’s Hospital of Philadelphia

Associate Professor, Pediatrics and Dermatology

Perelman School of Medicine at the University of Pennsylvania

Philadelphia, Pennsylvania

 

Albert C. Yan, has no relevant financial relationships with any commercial interests.

 

Statement of Professional Practice Gap(s)

Acne vulgaris, a follicular disorder that affects susceptible pilosebaceous follicles, is characterized by both noninflammatory and inflammatory lesions. Acne is the most common skin disease in the United States, affecting nearly 17 million individuals at any given time. Although it is most common in adolescents and young adults (85% of individuals between 12 and 24 years of age develop acne), acne may be seen at any age. The disease frequently is seen in preadolescents, and its occurrence in children as young as 7 years of age is not rare.

 

Untreated acne can leave permanent scars and, as such, create psychosocial issues for preadolescents, adolescents, young adults, and adult patients. Emerging therapies and regimens offer dermatologists a broader range of options to improve  tolerability, sustain positive clinical outcomes, and effectively treat a diverse patient population. Treatment of acne depends on the type, extent, and severity of the condition. Topical treatments are indicated alone for mild to moderate comedonal lesions and superficial inflammatory (papular or pustular) and nonscarring acne. Systemic treatments—including oral antibiotics—are indicated for moderate to severe manifestations (scarring or nonscarring) and patients with persistent hyperpigmentation. The current guidelines for acne management recommend the use of combination regimens in order to address multiple aspects of acne pathogenesis. It is generally recommended that a retinoid be used early in the treatment regimen. For best outcomes, patient care should be individualized.

 

To achieve this goal of personalized therapy patients of any age with acne, clinicians must stay informed about the proper use of existing therapies and the impending availability and anticipated appropriate use of emerging options. Furthermore, although randomized, controlled clinical trials of new and existing medications more frequently are including patients less than 12 years of age in study populations, to date all but a few prescription medications used to treat acne are approved by the US Food and Drug Administration for use in patients as young as 12 years of age. It is important for clinicians to have the benefit of the opinions  of experts to ensure that these medications are used appropriately and safely in younger pediatric patients.

 

This supplement addresses these needs and also provides an educational handout for the parents of younger pediatric patients to guide clinicians in helping families appropriately manage acne at home.

 

Target Audience

The target audiences for this educational supplement are dermatologists, pediatricians, and other health care professionals involved in the treatment of pediatric patients with acne.

 

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess and classify acne vulgaris in pediatric patients, including preteen/preadolescent patients.
  • Describe the topical and systemic medications available and suitable for use in pediatric patients with acne, and note specifically which medications are indicated and contraindicated in pediatric patients less than 12 years of age.
  • Discuss the evidence supporting how early treatment of acne changes the course of the disease in younger pediatric patients.
  • Select the type of medication and route of delivery appropriate for individual patients, based on age, severity of disease, and other factors.

 

Joint Sponsorship

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville School of Medicine Continuing Health Sciences Education (CHSE) and Skin Disease Education Foundation, an Elsevier business. CHSE is accredited by the ACCME to provide continuing education for physicians.

 

Designation Statement

CHSE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Copyright © 2011 Elsevier Inc.


click me